EXMceuticals’ mission is to operate large scale cannabis and hemp farms in an environmentally responsible manner, according to the Good Agricultural Practices (GAP), and following the Good Manufacturing Practices (GMP), to produce low cost and large volume high quality pharmaceutical grade cannabinoid ingredients for wholesaling in the international market.

EXMceuticals business model is strategically designed to harmonize with the global recognition of certain cannabis ingredients as a natural alternative to conventional pharmaceutical drugs, and the large increases in cannabis derived ingredients required to meet the demands of the nutraceutical, therapeutic and cosmetic industries.

EXMceuticals offers its partners and clients the most secure cannabinoid ingredients supply chain that exists in the cannabis industry, at the lowest production costs.
BOARD OF DIRECTORS

JOHN ANDERSON
Chairman

CHRIS GULKA
Board Member & Chief Financial Officer

MICHEL PASSEBON
Chief Executive Officer

MORTEN BORCH
Board Member

BOBBY DOYON
Board Member
JOHN ANDERSON
EXM Ceuticals Inc.
Chairman

Mr. Anderson is the chairman of Purplefish Capital Management Ltd., an independent corporate finance advisory firm with offices in Vancouver, Geneva, and Beijing. Purplefish works with companies to assist them in achieving strategic and financial objectives and attract capital for business development and growth. Over the past 25 years, Mr. Anderson has been instrumental in funding, helping to fund, and managing numerous companies; and has successfully raised over $500 million in equity for a number of public and private companies in the United States, Canada and Europe. He has been directly responsible for numerous initial public offerings and cross-border public listings.

MICHEL PASSEBON
EXM Ceuticals Inc.
Chairman
EXM Ceuticals Farming B.V.
Chairman & CEO

Mr. Passebon earned a diploma in Agro-Engineering in France. He completed his master’s degree in Project Management at the Université du Québec. Mr. Passebon is a senior executive and engineer with over 35 years of experience in the construction, management, and leadership of projects at the international level. His extensive and varied experience includes infrastructure, industry, environment, services, and logistics. Mr. Passebon has worked on long-term assignments in a dozen countries, giving him vast international experience and fuelling his keen knowledge of people and culture. He was the lead project manager in the development, implementation, and operation of a large-scale stevia farming and sweeteners extraction venture with offices in France and farm operations in Angola and Rwanda.

CHRIS GULKA
EXM Ceuticals Inc.
Chief Financial Officer

Mr. Gulka is a chartered accountant and a chartered financial analyst with over 24 years of business experience. He has been a director and officer of many public companies. Mr. Gulka gained extensive experience in the securities markets and with securities regulation by working for the Alberta Securities Commission as a financial analyst.
BOBBY DOYON  
EXM Ceuticals Inc.  
Board Member

Mr. Doyon is a senior partner at the Joli-Coeur Lacasse law firm where he works in the business and taxation departments. He provides support on a regular basis to entrepreneurs in their current operations and specific projects. He also negotiates and acts on their behalf with government agencies to obtain required project authorizations.

MORTEN BORCH  
EXM Ceuticals Inc.  
Board Member

After graduating from the University of Oslo with a Master of Law, Mr. Borch initially worked in private banking for DnB NOR, followed by positions focusing on tax and competition issues. He subsequently became a judge for two years prior to being appointed head of the legal department in Norske Skogindustrier ASA, specializing in mergers and acquisitions. In recent years he has continued these activities as a private practitioner in his own firm and sits on the board of several private investment companies.

MARC BERNIER  
EXM Ceuticals Holdings B.V.  
Chief Strategy Officer

Mr. Bernier has over 20 years of experience in project development, project implementation, and market development. He has been the lead advisor to several sovereign entities to negotiate and obtain Moody’s and Fitch credit ratings, bond issuance for sovereign infrastructure projects, and the creation of SPV’s to fund and operate sovereign-owned infrastructure companies. Over this time, Mr. Bernier acquired a wide range of experiences in the development and operation of private, public, and sovereign large-scale projects.
JULIE LEMIEUX
EXM Ceuticals Farming B.V.
Chief Operation Effectiveness Officer

Mrs. Lemieux has over 20 years of experience in business process improvements assisting large and small corporations across Canada attain new levels of success and implement sustainable organizational change. She has facilitated the reorganization of operational processes to improve efficiency and align strategic priorities for governments, major oil and gas companies, environmental and engineering firms, port authorities, large transportation organizations and indigenous groups in Canada. Mrs. Lemieux has managed various multidisciplinary teams situated around the world. She is particularly interested in Lean Six Sigma transformation with a focus on continuous improvement. She sits on many committees for the International Ski Federation representing Canada.

RICHARD LANGE
EXM Ceuticals Financials B.V.
Chief Compliance Officer

Over the last 30 years, Mr. Lange has gained plenty of international business knowledge. His specializations cover fields such as project integration, infrastructure projects, venture capital financing, and structured finance. He has extensive experience in investment, business acquisitions, shares placement, joint venture creation, and financing, as well as public and private partnerships. He has financed multiple companies, including Garda, Boomerang, and D-Box, by listing them on the Canadian Securities Exchange, and has acted as investment advisor for several private and public companies.

YVES BARIBEAU
EXM Ceuticals Farming B.V.
Director Construction & Engineering

Mr. Baribeau holds a degree in Naval Architecture from the Maritime Institute of Quebec which he received in 1990. He also has a bachelor’s degree in Mechanical Engineering from École de Technologie Supérieure (ETS), which he completed in 1997 in Montreal, Canada. Mr. Baribeau is a senior executive and engineer with over 20 years of experience in construction and management of complex projects in Canada and in foreign countries. Mr. Baribeau worked as Vice-President Marine Engineering for IT International Telecom where he was responsible for the engineering department as well as managing the company’s fleet of cable laying vessels and portable cable laying equipment, the planning and coordination of all activities related to international projects for submarine cable installations, in countries such as the United Arab Emirates, France, Bahamas, Brazil and Canada.
Mrs. Charmier obtained a PhD in Organic Chemistry and a Master of Science in Chemistry from the Université Blaise Pascal in France. She is a Professor as well as Director of the Biotechnological Engineering department and the postgraduate courses in Circular Economy at Universidade Lusófona (ULHT) in Lisbon, Portugal. Her main scientific areas of interest and expertise are: organic ligands reactivity, metal-mediated organic synthesis, coordination chemistry, cycloaddition reactions, catalysis, heterocycles, microwave assisted-promoted synthesis, biocatalysis, biopolymers, bio-based materials, extraction of plants and fruits, valorization of olive, beer and wine wastes using green technologies, study of the biological properties of extracts (antimicrobial, anti-tumoral, antioxidant activities) and their application in health (hospital infections, neurodegenerative diseases) and food. Mrs. Charmier has published over 26 scientific papers, has been a speaker at 35 scientific conferences, and holds 3 patents.

Mr. Paiva holds a Ph.D. degree in Chemical Engineering – Thermodynamics and Biocatalysis from the Technische Universität Hamburg-Harburg in Germany. He was a Postdoctoral researcher at REQUIMTE, a non-profit scientific organization, working on the “Biodiesel Production from Green Sources Using Supercritical Technology” project. Over the years, he has held fellowships in multiple research projects: “Production and Characterization of Particles Using Supercritical Fluids”; “Characterization of Micro/macromulsions in CO2”; “Computational Fluids Mechanics and Process Dynamics in Supercritical Extraction Columns with Structured Packing and Static Mixers”; “Adsorption of Gas Hydrocarbons in Activated Carbon at Low and Medium Pressures”. Mr. Paiva has published over 30 scientific papers in international peer-reviewed journals.

Dr. Drogoul, PhD in Psychiatry, is a Doctor in Medicine and an accomplished Psychiatrist who has published over 30 scholarly articles in peer review magazines as well as published books on psychiatry. Dr. Drogoul, resides in France, where he is a clinical practitioner in psychiatry and a Professor, of more then 20 years, at the Paris Diderot University. He is the publication director of Institutions, a reputed institutional psychotherapy magazine and has participated in multiple research projects over the years, including participation in research and committees focused on the effects of cannabinoids.
CHRISTOPHE JANICOT
EXM Ceuticals Farming B.V.
Director Laboratory Operations

Mr. Janicot obtained his Bio-medical Engineer Diploma in France. Mr. Janicot is a recognized medical and laboratory electronics and informatics expert. His experience includes executive positions at large cosmetics, food products and pharmaceutical laboratories where he managed lab workforces ranging between 20 to over 100 employees. He has designed vegetal extraction protocols and equipment; overseen ISO 9001 implementa-tions; implemented large scale Computer Assisted Production Management systems; organized cooperation agreements between European and international universities; worked on production automatization projects; designed and implemented large scale quality control and equipment maintenance programs.

FERDINAND MINGA KWETE
DRCongo Subsidiary
Chief Executive Officer

Born in the Democratic Republic of Congo, Mr. Minga received a degree in chemistry and biology and completed a bachelor’s degree in social science. Mr. Minga worked as a lab technician on cell culture for DSM Biologics for 3 years. Mr. Minga has held multiple executive level positions with Moisson Montreal, the largest food bank in Canada. He worked on a myriad of projects including the implementation of sustainable energy solutions for their storage facilities, as director of procurement, as director of the food preparation division as well as having developed and implemented the Moisson Montreal IT department. Mr. Minga was for a period the acting General Manager of Moisson Montreal.

DENIS TSHIMBALANGA
DRCongo Subsidiary
Director Operation

Born in the Democratic Republic of Congo, Mr. Tshimbalanga received his Engineering degree from the Genova University in Italy. Mr. Tshimbalanga, has over 30 years of experience working as a senior executive in the construction of large scale projects in Canada, North America and the Democratic Republic of Congo (DRC). Mr. Tshimbalanga was the Director of Operation for the Cie du Kasai et de l’Equateur (CKE), a large agro-industrial company specializing in the production of palm oil, latex and coffee, where he oversaw a fleet of over 400 vehicles, 5 boats and over 3,000 employees.
AFRICA HAS AN AGGREGATED POPULATION OF OVER 1.2 BILLION AND REPRESENTS A CLEAR MARKET OPPORTUNITY FOR CANNABIS BASED PHARMACEUTICAL PRODUCTS.

EXMceuticals KUBA Plantation & Processing
License obtained
10,000+ acres
Unlimited expansion capacity
DRC population 78,700,000

EXMceuticals KENYA Agro-Industrial Park
In process of application
5,000+ acres
Unlimited expansion capacity
Kenyan population 48,400,000

EXMceuticals GONDAR Agro-Industrial Park
License applied
5,000+ acres
Unlimited expansion capacity
Ethiopian population 102,400,000

EXMceuticals KAMPALA Plantation & Processing
License obtained by local partner
45+ acres
Unlimited expansion capacity
Uganda population 41,500,000

Each license allows us to grow cannabis and hemp, and to produce and export any volume of psychotropic and non-psychotropic cannabis and hemp base ingredients.
EXM Ceuticals Inc. (EXMceuticals), through a subsidiary, holds a license, in the Kuba Kingdom, Democratic Republic of Congo, for the cultivation cannabis and hemp, and processing and export of psychotropic and non-psychotropic cannabinoid ingredients. For its Kuba plantation, EXMceuticals has secured 10,000+ acres of organic farmland and expansion rights representing in excess of 100,000 continuous acres.

EXMceuticals currently has 20,000+ cannabis plants growing on its Kuba plantation and had its first harvest at the end of 2017. Harvested products are, at this stage, dried and stored for subsequent extraction of target ingredients.

EXMceuticals has entered into a Memorandum of Understanding with Prime Rancher Ltd (PRL) to acquire the controlling rights, which will allow EXMceuticals to produce, transform and export psychotropic and non-psychotropic cannabinoid ingredients from Uganda.

EXMceuticals is in the final phase of obtaining licenses in other regions of the African continent, including two Agro-Industrial Park, each of 10,000+ acres encompassing a free trade zone. Each Agro-Industrial Park will allow the cultivation of cannabis and hemp, and the processing, transformation and export of psychotropic and non-psychotropic cannabinoid ingredients.
The Canadian market for medical and recreational cannabis is estimated to represent in excess of 9 billions Canadian dollars (yearly) in retail sales.

**Europe** has an aggregated population of over 740 million and represents a clear market opportunity for cannabis based pharmaceutical, therapeutic and nutraceutical products.

EXMceuticals GFR Pharma JV Distribution & Manufacturing
Application in process
Canadian population 36,200,000

EXMceuticals Portugal JV Research, Nursery, Manufacturing & Distribution
Application in process
Portuguese population 10,300,000

The Canadian market for medical and recreational cannabis is estimated to represent in excess of 9 billions Canadian dollars (yearly) in retail sales.
EXMceuticals is in the process of applying for a license in Portugal for the establishment of a laboratory for research, a nursery, and center for processing and distribution. In addition to its more scientific mandate the facility will be used by EXMceuticals as its base for distribution in the EU.

EXMceuticals has entered into a Memorandum of Understanding with GFR Pharma Inc (gfrpharma.com) under which GFR Pharma and EXMceuticals are establishing a joint venture company which will file to obtain a license, from Health Canada, to import and distribute cannabinoid ingredients, as well as produce white label retail products containing cannabinoid ingredients, through GFR Pharma facilities.

GFR Pharma is a pre-eminent full-service contract manufacturer, packager and formulation expert of superior quality tablet, capsule, powder, and liquid natural health products for the Canadian, U.S., and international markets.
EXMceuticals activities are focused on the sustainable cultivation of cannabis and hemp, and production of pharmaceutical grade psychotropic and non-psychotropic cannabis and hemp ingredients for the pharmaceutical, therapeutical and nutraceutical industries.

- Specification definitions for testing, design, and equipment is complete and the equipment that will allow us to process in excess of 10,000 kg of raw material per month has been ordered.
- Equipment in operation. More than 20,000+ plants in the ground.
- Nurseries, laboratories, and other ancillary facilities are currently being built.
- Increase in our processing capacity to 20,000 kg of raw material to be in operation.
- Subsequent regular increases to meet market demands.

JANUARY 2018

NOVEMBER 2018
PRODUCT LINE

EXMceuticals utilizes the CO2 hypercritical method for the extraction of its pharmaceutical grade cannabinoid ingredients line of product. The CO2 hypercritical method, which is chemical free, offers high molecule separation strength while allowing us to offer our clients the best natural and organically produced ingredients available in the market.

Collaborating with renowned scientists, EXMceuticals continues to evolve newer, more efficient processes to meet the stringent needs and evolving needs of the pharmaceutical, therapeutical, nutraceutical and cosmetic industries.

According to scientists in the field, cannabis contains more than 480 molecules of sugars, terpenes, flavonoids, hydrocarbons, amino acids...

At this stage, as research into molecules contained in cannabis is still in its infancy, our production focuses on two molecules:

- **THC**: a psychotropic drug has been proven effective in the fields of pain management, appetite control, anxiety, managing side effects of chemotherapy. Additional applications are expected to be added to the list as research is ongoing in regards to its benefits in neurodegenerative diseases and oncology.

- **CBD**: a non-psychotropic drug has been proven effective against acne, anxiety, depression, epilepsy and degenerative diseases such as Parkinson’s. Additional applications are expected to be added to the list as research is ongoing in regards to its benefits in oncology as the molecule has already demonstrated in vitro activity.
EXMceuticals, through its pool of contract researchers and academic relationships, focuses on developing gentle and efficient methods for extracting molecules while also supporting research on new applications for THC and CBD, and research on new potential applications for other molecules contained in cannabis.

EXMceuticals, through its internal and external researchers, can provide assistance to its customers in a wide array of scientific activities, including galenic formulation, evidence of activity, and pharmaceutical studies.
QUALITY ASSURANCE & PRODUCT TESTING

EXMceuticals Quality Assurance program and systems are designed to meet or exceed top industry standards. In particular, the EXMceuticals Quality Assurance program respects all the GMP’s and traceability rules, as well as security and recordkeeping rules established by international standards or by countries of destination of our products.

The company Quality Assurance program is designed to ensure that EXMceuticals can demonstrate and guarantee to its clients or regulatory bodies the security of its processes, their reproducibility, and the quality of its products at all time.

From planting to transformation, our production is framed by strict controls and procedures. EXMceuticals management is committed to the absolute respect of the rules established in its Quality Manual. A exhaustive employee training program for employees of every level further ensures compliance with our established standards.

The pharmaceutical grade cannabinoid ingredients produced by EXMceuticals are also subject to strict internal and external quality control procedures, including the controls of physico chemical, active ingredient contents and pH. In particular, organoleptic for color, viscosity, and other sensory properties; and bacteriological to confirm absence of pathogens, total flora, spores, molds and pesticides.
EXMceuticals offers large scale pharmaceutical, therapeutical, and nutraceutical companies cannabis products manufactured with unique advantages:

- The largest (aggregated) cannabis growth spaces with each regional production facility having a laboratory and ingredients extraction capacity on-site;
- A team with proven experience in agriculture, hypercritical CO2 extraction, laboratory and product placement;
- Innovative business model allowing pharmaceutical, therapeutical and nutraceutical market leaders to:
  - Scale up to easily accommodate rapid increases in supply requirements;
  - Break down production capacity over multiple geographical areas, ensuring a highly dependable and the most secure supply-chain;
  - Work with a supplier that has the lowest operating costs in the industry due to low labour cost, low governmental regulatory costs and low construction costs;
  - Work with a team with a proven track record of managing operations, compliance to regulations, standards, and inspections procedures across multiple jurisdictions in Africa and elsewhere;
- Canadian and EU based import & export trans-shipment facilities and quality & purity control laboratories.
2% of gross sales resulting from each local production facility are donated to a community development fund aimed at bettering the lives in those communities.
ESTIMATES OF MARKET SIZE

The legal global cannabis market is poised for growth of more than 1,000% over the next decade and could reach $140 billion dollars by 2027, according to a new analysis by European investment bank Bryan, Garnier & Co.

Global alcohol giant Constellation Brands made its move by buying a 9.9% stake in Canada’s largest licensed producer, Canopy Growth, for 245 million Canadian dollars (USD190 million), plus options to raise its stake to just under 20%.

Marijuana sales in North America reached $6.73 billion in 2016—reflecting 34% growth over 2015 ($5.04 billion), according to Arcview Market Research/BDS Analytics. The research firm projects sales to jump to $21.6 billion by 2021, representing a 26% compound annual growth rate (CAGR).

The second edition of the European Cannabis Report—produced by London-based advisory group Prohibition Partners—suggests that with 12% of the [European] continent’s 739 million people being either “irregular and intensive” cannabis consumers. Analysts anticipate the European cannabis market to net roughly 56.2 billion dollars yearly within next few years as more countries within the EU legalize and regulate medical and recreational cannabis.
NOVA University of Lisbon

Founded in 1973, it is the youngest of the public universities in the Portuguese capital city, earning its name as the “New” (NOVA) University of Lisbon.

This Institution has more than 19,000 students, 1,691 Professors and 804 staff. NOVA is recognized as one of the world’s best universities having being ranked number 312 in the world by Times Higher Education in 2014.

NOVA.ID.FCT

acts as the legal front institution of multiple research units, from different scientific fields, carrying out research work and managing financial and administratively R&D projects for Universidade Nova de Lisboa.

NOVA.ID.FCT promotes and facilitates scientific research, technology and development services to society; organizes qualified human resources training and consulting expertise and knowledge dissemination and technology transfer.

Universidade Lusófona

de Humanidades e Tecnologias (Lusophone University of Humanities and Technologies) is the largest Portuguese private university, and the main institution of Grupo Lusófona, which administers other universities and colleges in Portugal, Brazil, Cape Verde, Angola, Guinea-Bissau and Mozambique.
CONTACT US

CANADA HEAD OFFICE
24 West 4th Avenue
Vancouver, British Columbia
Canada, V5Y 1G3
Info@EXMceuticals.com

AFRICA HEAD OFFICE
Addis Ketema Sub City, Woreda 08,
No. 710, 7th floor
Addis Ababa, Ethiopia
AfricaHO@EXMceuticals.com

INVESTORS
Investors@EXMceuticals.com